Patents Assigned to Victoria Link Limited
  • Bacterial nitroreductase enzymes and methods relating thereto
    Patent number: 10357577
    Abstract: The invention relates generally to bacterial nitroreductase enzymes and methods of use thereof: more particularly, although not exclusively, the enzymes have use in non-invasive imaging techniques, monitoring of therapeutic cell populations and gene-directed enzyme prodrug therapy. The invention also relates to the use of bacterial nitroreductase enzymes in radioimaging and/or ablation of biological agents and to compositions of use in such methods.
    Type: Grant
    Filed: July 18, 2011
    Date of Patent: July 23, 2019
    Assignees: AUCKLAND UNISERVICES LIMITED, VICTORIA LINK LIMITED
    Inventors: Christopher Paul Guise, David Francis Ackerley, Amir Ashoorzadeh, Janine Naomi Copp, Jack Urquhart Flanagan, Alexandra Marie Mowday, Adam Vorn Patterson, Gareth Adrian Prosser, Jeffrey Bruce Smaill, Sophie Phillipa Syddall, Elsie May Williams
  • Treatment of infections using MTAN inhibitors
    Patent number: 10294233
    Abstract: Methods of treating infections due to Helicobacter pylori (H. pylori), in particular in subjects having a peptic ulcer, are disclosed where the methods comprise administering inhibitors of H. pylori MTAN (5?-methylthioadenosine nucleosidase) to the subject.
    Type: Grant
    Filed: September 20, 2018
    Date of Patent: May 21, 2019
    Assignees: Albert Einstein College of Medicine, Victoria Link Limited
    Inventors: Vern L. Schramm, Keith Clinch, Shivali Ashwin Gulab
  • Salt and polymorphic forms of (3R,4S)-L-((4-amino-5H-pyrrolo[3,2,-D]pyrimidin-7-yl)methyl)-4(methylthiomethyl)pyrodin-3-ol(MTDIA)
    Patent number: 10227351
    Abstract: The invention relates to salt forms of (3R,4S)-1-((4-amino-5H-pyrrolo[3,2-d]pyrimidin-7-yl)methyl)-4-(methyl-thiomethyl)pyrrolidin-3-ol, as well as polymorphic forms of the salts. The invention further relates to processes for preparing the salt forms and to the use of the salt forms in the treatment of diseases and disorders where it is desirable to inhibit 5?-methylthioadenosine phosphorylase (MTAP).
    Type: Grant
    Filed: May 31, 2018
    Date of Patent: March 12, 2019
    Assignee: Victoria Link Limited
    Inventors: Gary Brian Evans, Peter Michael Kelly, Peter Charles Tyler
  • TREATMENT OF H. PYLORI INFECTIONS USING MTAN INHIBITORS
    Publication number: 20190016730
    Abstract: Methods of treating infections due to Helicobacter pylori (H. pylori), in particular in subjects having a peptic ulcer, are disclosed where the methods comprise administering inhibitors of H. pylori MTAN (5?-methylthioadenosine nucleosidase) to the subject.
    Type: Application
    Filed: September 20, 2018
    Publication date: January 17, 2019
    Applicants: ALBERT EINSTEIN COLLEGE OF MEDICINE, INC., VICTORIA LINK LIMITED
    Inventors: Vern L. Schramm, Keith Clinch, Shivali Ashwin Gulab
  • SALT AND POLYMORPHIC FORMS OF (3R,4S)-L-((4-AMINO-5H-PYRROLO[3,2,-D]PYRIMIDIN-7-YL)METHYL)-4(METHYLTHIOMETHYL)PYRODIN-3-OL(MTDIA)
    Publication number: 20180319803
    Abstract: The invention relates to salt forms of (3R,4S)-1-((4-amino-5H-pyrrolo[3,2-d]pyrimidin-7-yl)methyl)-4-(methyl-thiomethyl)pyrrolidin-3-ol, as well as polymorphic forms of the salts. The invention further relates to processes for preparing the salt forms and to the use of the salt forms in the treatment of diseases and disorders where it is desirable to inhibit 5?-methylthioadenosine phosphorylase (MTAP).
    Type: Application
    Filed: May 31, 2018
    Publication date: November 8, 2018
    Applicant: VICTORIA LINK LIMITED
    Inventors: Gary Brian Evans, Peter Michael Kelly, Peter Charles Tyler
  • Treatment of H. pylori infections using MTAN inhibitors
    Patent number: 10118928
    Abstract: Methods of treating infections due to Helicobacter pylori (H. pylori), in particular in subjects having a peptic ulcer, are disclosed where the methods comprise administering inhibitors of H.
    Type: Grant
    Filed: February 6, 2015
    Date of Patent: November 6, 2018
    Assignees: Albert Einstein College of Medicine, Inc., Victoria Link Limited
    Inventors: Vern L. Schramm, Keith Clinch, Shivali Ashwin Gulab
  • Amino sphingoglycolipid analogues
    Patent number: 10046046
    Abstract: The invention relates to amino sphingoglycolipid analogues and peptide derivatives thereof, compositions comprising these compounds and methods of treating or preventing diseases or conditions using such compounds, especially diseases or conditions relating to cancer, infection, atopic disorders, autoimmune disease or diabetes.
    Type: Grant
    Filed: June 5, 2015
    Date of Patent: August 14, 2018
    Assignee: Victoria Link Limited
    Inventors: Regan James Anderson, Benjamin Jason Compton, Colin Malcolm Hayman, Ian Francis Hermans, Karen Anne Johnston, Gavin Frank Painter
  • Methods of detecting and measuring glutamine and analogues thereof, and methods related thereto
    Patent number: 9995750
    Abstract: Method for the detection of glutamine and its analogs are provided by the present disclosure. Also provided are methods for measuring the levels of glutamine and its analogs, including diagnostic methods. Further provided are methods that utilize glutamine analogs for the synthesis of colored pigments and other useful agents. The methods comprise the use of a nonribosomal peptide synthetase (NRPS) under conditions to produce an indigoidine or indigoidine-related pigment.
    Type: Grant
    Filed: December 5, 2014
    Date of Patent: June 12, 2018
    Assignee: Victoria Link Limited
    Inventors: David Francis Ackerley, Alistair Sinclair Brown, Katherine Jane Robins
  • Salt and polymorphic forms of (3R,4S)-L-((4-amino-5H-pyrrolo[3,2,-d]pyrimidin-7-yl)methyl)-4(methylthiomethyl)pyrodin-3-ol(MTDIA)
    Patent number: 9994574
    Abstract: The invention relates to salt forms of (3R,4S)-1-((4-amino-5H-pyrrolo[3,2-d]pyrimidin-7-yl)methyl)-4-(methyl-thiomethyl)pyrrolidin-3-ol, as well as polymorphic forms of the salts. The invention further relates to processes for preparing the salt forms and to the use of the salt forms in the treatment of diseases and disorders where it is desirable to inhibit 5?-methylthioadenosine phosphorylase (MTAP).
    Type: Grant
    Filed: November 12, 2013
    Date of Patent: June 12, 2018
    Assignee: Victoria Link Limited
    Inventors: Gary Brian Evans, Peter Michael Kelly, Peter Charles Tyler
  • Furo[3,4-]pyran compounds and pharmaceutical uses
    Patent number: 9956198
    Abstract: Furo[3,4-b]pyran compounds similar in chemical structure to the natural product known as TAN-2483B and their use for treating cancer, osteoporosis, Type 2 diabetes, or immune diseases.
    Type: Grant
    Filed: December 13, 2016
    Date of Patent: May 1, 2018
    Assignee: Victoria Link Limited
    Inventors: Joanne Elizabeth Harvey, Russell James Hewitt, Rathnayake Mudiyanselage Kalpani Kumari Somarathne
  • 3-hydroxypyrrolidine inhibitors of 5?-methylthioadenosine phosphorylase and nucleosidase
    Patent number: 9957272
    Abstract: The present invention relates to 3-hydroxypyrrolidine compounds of the general formula (1) which are inhibitors of 5?-methylthioadenosine phosphorylase or 5?-methylthioadenosine nucleosidase. The invention also relates to the use of these compounds in the treatment of diseases or conditions in which it is desirable to inhibit 5?-methylthioadenosine phosphorylase or 5?-methylthioadenosine nucleosidase including cancer, and to pharmaceutical compositions containing the compounds.
    Type: Grant
    Filed: November 10, 2016
    Date of Patent: May 1, 2018
    Assignees: Victoria Link Limited, Albert Einstein College of Medicine, Inc.
    Inventors: Gary Brian Evans, Alistair Ian Longshaw, Vern L. Schramm, Peter Charles Tyler
  • Saccharide dendritic cluster compounds as inhibitors of BACE-1
    Patent number: 9879041
    Abstract: The invention relates to dendritic compounds, the use of these compounds as pharmaceuticals, pharmaceutical compositions containing the compounds, processes for preparing the compounds, and methods of treating diseases or conditions in which it is desirable to inhibit ?-secretase.
    Type: Grant
    Filed: November 28, 2013
    Date of Patent: January 30, 2018
    Assignees: Victoria Link Limited, University of Liverpool
    Inventors: Peter Charles Tyler, Olga Vladimirovna Zubkova, Jeremy E. Turnbull
  • Safety material and system
    Patent number: 9865862
    Abstract: Compositions and methods for deterring and/or visually identifying oral contact with objects that are hazardous upon oral contact or ingestion are disclosed. The compositions generally comprise a colorant and a carrier and may further comprise an aversive agent, a salivating agent, and/or an emetic. The compositions may be particularly useful for application to batteries, including button cells.
    Type: Grant
    Filed: November 6, 2015
    Date of Patent: January 9, 2018
    Assignee: Victoria Link Limited
    Inventor: Jeongbin Ok
  • Dendritic core compounds
    Patent number: 9828341
    Abstract: The invention relates to compounds that are useful for the preparation of dendrimer compounds, the use of these compounds for preparing dendrimers and processes for preparing the compounds.
    Type: Grant
    Filed: November 28, 2013
    Date of Patent: November 28, 2017
    Assignee: Victoria Link Limited
    Inventors: Peter Charles Tyler, Olga Vladimirovna Zubkova
  • Conjugate compounds
    Patent number: 9764037
    Abstract: The invention relates to sphingoglycolipid analogs and peptide derivatives thereof, which are useful in treating or preventing diseases or such as those relating to infection, atopic disorders, autoimmune diseases or cancer.
    Type: Grant
    Filed: December 6, 2013
    Date of Patent: September 19, 2017
    Assignee: Victoria Link Limited
    Inventors: Regan James Anderson, Benjamin Jason Compton, Colin Malcolm Hayman, Ian Francis Hermans, David Samuel Larsen, Gavin Frank Painter, Franca Ronchese
  • Sphingoglycolipid analogues
    Patent number: 9717790
    Abstract: The invention relates to sphingoglycolipid analogues which are useful in treating or preventing diseases and conditions such as those relating to infection, atopic disorders, autoimmune diseases or cancer.
    Type: Grant
    Filed: June 10, 2014
    Date of Patent: August 1, 2017
    Assignee: Victoria Link Limited
    Inventors: Regan James Anderson, Benjamin Jason Compton, Colin Malcolm Hayman, Ian Francis Hermans, Karen Anne Johnston, David Samuel Larsen, Gavin Frank Painter
  • 3-HYDROXYPYRROLIDINE INHIBITORS OF 5'-METHYLTHIOADENOSINE PHOSPHORYLASE AND NUCLEOSIDASE
    Publication number: 20170166573
    Abstract: The present invention relates to 3-hydroxypyrrolidine compounds of the general formula (1) which are inhibitors of 5?-methylthioadenosine phosphorylase or 5?-methylthioadenosine nucleosidase. The invention also relates to the use of these compounds in the treatment of diseases or conditions in which it is desirable to in 5?-methylthioadenosine phosphorylase or 5?-methylthioadenosine nucleosidase including cancer, and to pharmaceutical compositions containing the compounds.
    Type: Application
    Filed: November 10, 2016
    Publication date: June 15, 2017
    Applicants: VICTORIA LINK LIMITED, ALBERT EINSTEIN COLLEGE OF MEDICINE, INC.
    Inventors: Gary Brian Evans, Alistair Ian Longshaw, Vern L. Schramm, Peter Charles Tyler
  • OPTIMISATION METHOD OF A POLYNUCLEOTIDE SEQUENCE
    Publication number: 20170115281
    Abstract: The present invention provides for a method of optimisation of a polynucleotide sequence for use in an aptamer based assay, comprising adding additional bases to the ligand binding domain. The invention also covers methods of detecting target molecules in a sample using 5 optimised polynucleotide sequences in a suitable detection assay.
    Type: Application
    Filed: May 15, 2015
    Publication date: April 27, 2017
    Applicant: Victoria Link Limited
    Inventors: Justin Hodgkiss, Omar Alsager, Shalen Kumar, Kenneth McNatty
  • Organic compounds as proantigens for natural killer T cells
    Patent number: 9586985
    Abstract: This invention relates to sphingoglycolipid analogs, compositions comprising these compounds, processes for preparing the compounds, and methods of treating or preventing diseases or conditions using the compounds, such as diseases or conditions relating to infection, atopic disorders, autoimmune disease, diabetes or cancer.
    Type: Grant
    Filed: July 26, 2013
    Date of Patent: March 7, 2017
    Assignee: VICTORIA LINK LIMITED
    Inventors: Benjamin Jason Compton, Colin Malcolm Hayman, Ian Francis Hermans, David Samuel Larsen, Gavin Frank Painter, Regan J. Anderson
  • Furo[3,4-b]pyran compounds and pharmaceutical uses
    Patent number: 9556194
    Abstract: Furo[3,4-b]pyran compounds similar in chemical structure to the natural product known as TAN-2483B and their use for treating cancer, osteoporosis, Type 2 diabetes, or immune diseases.
    Type: Grant
    Filed: December 1, 2014
    Date of Patent: January 31, 2017
    Assignee: VICTORIA LINK LIMITED
    Inventors: Joanne Elizabeth Harvey, Russell James Hewitt, Rathnayake Mudiyanselage Kalpani Kumari Somarathne